Decrease in Skin Prion-Seeding Activity of Prion-Infected Mice Treated with a Compound Against Human and Animal Prions: a First Possible Biomarker for Prion Therapeutics

Mingxuan Ding¹,² · Kenta Teruya³ · Weiguanliu Zhang¹,² · Hae Weon Lee² · Jue Yuan² · Ayumi Oguma³ · Aaron Foutz² · Manuel V. Camacho² · Marcus Mitchell² · Justin J. Greenlee⁴ · Qingzhong Kong²,⁵ · Katsumi Doh-ura³ · Li Cui¹ · Wen-Quan Zou²,⁵

Received: 21 December 2020 / Accepted: 30 April 2021 / Published online: 13 May 2021
© The Author(s) 2021

Abstract
Previous studies have revealed that the infectious scrapie isoform of prion protein (PrPSc) harbored in the skin tissue of patients or animals with prion diseases can be amplified and detected through the serial protein misfolding cyclic amplification (sPMCA) or real-time quaking-induced conversion (RT-QuIC) assays. These findings suggest that skin PrPSc-seeding activity may serve as a biomarker for the diagnosis of prion diseases; however, its utility as a biomarker for prion therapeutics remains largely unknown. Cellulose ethers (CEs, such as TC-5RW), widely used as food and pharmaceutical additives, have recently been shown to prolong the lifespan of prion-infected mice and hamsters. Here we report that in transgenic (Tg) mice expressing hamster cellular prion protein (PrPC) infected with the 263K prion, the prion-seeding activity becomes undetectable in the skin tissues of TC-5RW-treated Tg mice by both sPMCA and RT-QuIC assays, whereas such prion-seeding activity is readily detectable in the skin of untreated mice. Notably, TC-5RW exhibits an inhibitory effect on the in vitro amplification of PrPSc in both skin and brain tissues by sPMCA and RT-QuIC. Moreover, we reveal that TC-5RW is able to directly decrease protease-resistant PrPSc and inhibit the seeding activity of PrPSc from chronic wasting disease and various human prion diseases. Our results suggest that the level of prion-seeding activity in the skin may serve as a useful biomarker for assessing the therapeutic efficacy of compounds in a clinical trial of prion diseases and that TC-5RW may have the potential for the prevention/treatment of human prion diseases.

Keywords Prions · Prion diseases · Cellulose ethers · Real-time quaking-induced conversion (RT-QuIC) · Serial protein misfolding cyclic amplification (sPMCA) · TC-5RW
Introduction

Prion diseases or transmissible spongiform encephalopathies are a group of neurodegenerative diseases affecting the central nervous system of humans and animals, including Creutzfeldt-Jakob disease (CJD), kuru, familial insomnia (FFI), Gerstmann-Sträussler-Scheinker (GSS) syndrome, and variably protease-sensitive prionopathy (VPSPr) in humans, and scrapie in sheep and goats, bovine spongiform encephalopathy (BSE), and chronic wasting disease (CWD) in elk and deer [1]. They have a long incubation period and a 100% fatality rate. All these diseases have detectable deposition in the brain of abnormal infectious misfolded prion protein (PrPSc), a molecular hallmark of prion diseases, which is derived from its normal cellular prion protein (PrPC) through a structural transition [2].

Our previous study revealed that autopsy skin tissues from sporadic CJD cadavers harbor PrPSc that exhibited seeding activity and infectivity [3] that has recently been confirmed not only with autopsy skin samples from CJD cadavers diagnosed neuropathologically but also biopsy skin samples from living CJD patients [4]. Moreover, in animal models including 263 K scrapie prion-infected hamsters and sporadic CJD (sCJD) prion-infected humanized transgenic (Tg) mice expressing human wild-type PrP, we further observed that skin PrPSc was detectable by real-time quaking-induced conversion (RT-QuIC) and serial protein misfolding cyclic amplification (sPMCA) assays long before clinical signs and brain lesions manifested [5]. These observations provide the proof-of-concept that skin PrPSc may be a biomarker for early preclinical diagnosis of prion diseases. However, it is unclear whether the level of prion-seeding activity in the skin can serve as a biomarker for assessing the efficacy of anti-prion therapeutics.

Cellulose ethers (CEs), a family of non-digestible, non-ionic, and water-soluble polysaccharide derivatives, are widely used as additives in food, pharmaceutical tablets, and personal care products [6, 7]. Doh-ura and co-workers first discovered that CEs including TC-5RW have a significant protective effect on prion infection of animals that were given before and after inoculation [8]. Other teams have also confirmed that this compound can prolong the incubation period of infected rodents expressing elk or deer PrP infected with different CWD prions [9, 10]. Moreover, a liposomal formulation of CEs was found successfully to lower the effective dose of CE in prion-infected cells [11].

In the present study, we investigate prion-seeding activity in skin samples from prion-infected Tg mice with or without TC-5RW treatment via RT-QuIC and sPMCA assays. We find that the prion-seeding activity in the skin of TC-5RW-treated mice becomes undetectable but remains detectable in vehicle-treated control mice. Moreover, we reveal that TC-5RW inhibits the amplification of hamster PrPSc from skin and brain tissues in RT-QuIC and sPMCA experiments. Additionally, our RT-QuIC assay reveals that TC-5RW is able to inhibit the seeding activity of PrPSc from CWD and various human prion diseases as well. Finally, in vitro direct incubation of TC-5RW with brain homogenates from hamster, elk, deer, or humans infected by various prions is found to decrease the levels of protease-resistant PrPSc (PrPres).

Materials and Methods

Reagents and Antibodies

TC-5RW was kindly provided by Shin-Etsu Chemical Co., Ltd. (Tokyo, Japan). Proteinase K (PK) was purchased from Sigma ALDRICH Co. (St. Louis, MO, USA). Protease inhibition cocktail tablets were purchased from Roche Diagnostics (Indianapolis, IN, USA). Reagents for enhanced chemiluminescence (ECL Plus) were from Thermo Scientific (Rockford, IL, USA). Anti-PrP mouse monoclonal antibody 3F4 [12, 13] and sheep anti-mouse IgG conjugated with horseradish peroxidase as a secondary antibody were purchased from Sigma Aldrich [14].

Animal Study

The animal experiment was performed following a protocol reviewed and approved by the Institutional Animal Care and Use Committee of Tohoku University (approval number 2016MdA-139). Thirteen hemizygous Tg7 mice at 6 to 10 weeks old obtained by a cross between Tg7 [15] and PrP-null mice [16] were inoculated intracerebrally with 20 μL of 1% (w/v) brain homogenate obtained from a terminally ill 263 K prion-infected hamster. On the day of inoculation, 8 mice were also injected with a single intraperitoneal injection of 1 mL of 50 mg/mL TC-5RW in saline, and the other 5 mice were inoculated with 1 mL of saline as vehicle-treated controls. Mice were monitored daily from inoculation until the terminal stage, at which time the mice exhibited akinesia (with a lack of grooming behavior, coordination, and para-chute reaction) or exhibited a rigid tail, an arched back, and weight loss of approximately 10% within 1 week [17]. The mice were sacrificed at the terminal stage. The time from inoculation to death was defined as the survival time. Skin samples from the back near the tail and brain samples were taken immediately after sacrifice as described previously [5]. The scissors and tweezers used for skin collection were handled with great care to avoid contamination from the brain to the skin or between mice. The skin samples were collected first before opening the skull for collecting brain tissues and
all devices were decontaminated after each use. The skin tissues were frozen on dry ice and stored in a −80 °C freezer for future use. Some of the brain samples were similarly frozen and kept in a freezer, while some were formalin fixed and paraffin embedded as described previously [18].

Paraffin-Embedded Tissue Blotting and Hematoxylin/Eosin Staining

Paraffin-embedded tissue (PET) blot analysis was performed for detection of PrPSc deposition in the brain as described previously [18]. In brief, 6-μm paraffin-embedded brain sections were cut and collected onto nitrocellulose membranes and then dried overnight at 60 °C. Membranes were dewaxed in xylene, followed by step-wise rehydration. After wetting with Tris-buffered saline-tween 20 (TBST) (10 mM Tris–HCl, pH 7.8, 100 mM NaCl, and 0.05% Tween-20), sections were digested with 250 μg/mL PK in a buffer (10 mM Tris–HCl, pH 7.8, 100 mM NaCl, and 0.1% Brij35) overnight at 55 °C. After washing with TBST, sections were treated with 3 M guanidine isothiocyanate for 30 min. After washing out guanidine using TBST, immunodetection was performed with an anti-PrP-C antibody, which recognizes residues 214–228 of mouse/hamster PrP (1:1500, Immuno-Biological Laboratories Co., Ltd., Gunma, Japan). The 3-μm paraffin-embedded brain sections serially adjacent to those used for PET blot analysis were stained with hematoxylin and eosin (H&E). Assessment of pathological changes including spongiform degeneration was conducted under a light microscope.

Preparation of Brain and Skin Samples

Skin samples (~ 50 mg each in weight, ~5 mm × 5 mm each in size) were taken with epidermis, dermis, and hypodermis three layers as described previously [5]. They were washed three times in 1 × Tris-buffered saline (TBS) to remove possible blood contamination and cut into small pieces in dishes. The 5% (w/v) skin homogenates were prepared in skin lysis buffer containing 10 mM Tris–HCl, 133 mM NaCl, 2 mM CaCl2, and 0.25% collagenase A (Roche), pH 7.4, and incubated in a shaker at 37 °C for 4 h. Mouse brain samples at 5% (w/v), hamster, and human autopsy brain samples at 10% (w/v) were homogenized in lysis buffer containing 125 mM NaCl, 12.5 mM EDTA, 12.5 mM Tris–HCl, 0.5% sodium deoxycholate, 0.5% NP-40, and pH 7.4, with a Mini-Beadbeater (BioSpec, Laboratory Supply Network, Inc., Atkinson, NH) shaking (1 min)-incubating on ice (2 min) cycle for 3 cycles. Frozen brain tissues from two white-tailed deer and a reindeer with CWD [19–21] were carefully dissected to avoid blood contamination as much as possible.

RT-QuIC Assay

RT-QuIC assays of skin from Tg7 mice and brain samples from 263 K-infected hamster, patients with different prion diseases, and CWD deer were performed as previously described [5], with minor modification. In brief, RT-QuIC reaction mix was composed of 1 × phosphate buffer pH 7.4, 0.17 M NaCl, 0.1 mg/mL homemade recombinant truncated Syrian golden hamster PrP90-231 [22], 10 μM Thioflavin T (ThT), 1 mM EDTA, and 0.001% SDS. Each well of a 96-well plate (Nunc) was loaded with 96 μL of reaction mix and seeded with 2 μL of Tg8 mouse skin homogenate at a final concentration of 10−3 or deer or human brain homogenate at a final concentration of 2 × 10−7. Seeds were spun at 5000 × g for 2 min at 4 °C prior to loading. To investigate the inhibitory effect of TC-5RW on prion-seeding activity in RT-QuIC, 2 μL of differing concentrations of TC-5RW was added to reaction wells before loading seeds. The plates were sealed with a plate sealer film (Nalgene Nunc International) and incubated at 55 °C for skin samples and 42 °C for brain samples in a BMG FLUOstar Omega plate reader with cycles of 1 min shaking (700 rpm double orbital) and 1-min rest throughout the indicated incubation time. ThT fluorescence intensity (450 ± 10-nm excitation and 480 ± 10-nm emissions; bottom read) was measured every 45 min. All samples were run in quadruplicate. The average fluorescence of each sample was determined by taking the average of all four replicates regardless of whether their ThT values were above the threshold described below. Samples with at least 2 out of 4 replicate wells above the determined threshold were considered positive. A ThT fluorescence threshold for a reaction to define the positive and negative cases was determined based on the mean ThT value of all negative control samples at 60 h, plus 3 standard deviations as previously described [5]. For comparison, the average ThT fluorescence was normalized as percentages with the highest fluorescence in each plate. The differences in prion-seeding activity may result in variable lag phase or lag time of prion aggregation, the time point when the ThT fluorescence of protein aggregates RT-QuIC starts to continuously increase [10]. So, the lag time of the RT-QuIC reaction was also used to compare prion-seeding activity among different prion diseases in our study.

Serial PMCA Analysis

Serial PMCA (sPMCA) assay as well as the preparation of PrPSc seeds and PrPC substrates were conducted as previously described [5, 23, 24] with minor modification. Briefly, to make the sPMCA PrPSc substrate, normal hamster or humanized Tg mouse brain tissues expressing human wild-type PrP (Tg40h) [13] were carefully dissected to avoid blood contamination as much as possible.
The normal hamster or humanized Tg mouse brain tissues were homogenized (10% w/v) in sPMCA conversion buffer containing 150 mM NaCl, 1% Triton X-100, 8 mM EDTA, pH 7.4, and the complete protease inhibitor mixture cocktail (Roche) in PBS, followed by centrifugation at 1000 g at 4 °C for 10 min to collect the supernatant (S1) fraction. Finally, the supernatant was mixed with 5 mg/mL heparin at 50:1. The substrates and seeds were kept at –80 °C until use. Each skin PrPSc seed was diluted in the substrate at the ratios 1:12.5 (8 μL seed in 100 μL mix) into 200 μL PCR tubes with 1 PTFE beads (diameter 3/32”) (Teflon, APT, RI) while 263 K-infected hamster brain homogenate seeds or sCJDMM1- or sCJDMM2-infected human brain homogenate seeds were diluted at the ratios 1:100 (1 μL seed in 100 μL mix) as positive controls. To detect the inhibitory effect of TC-5RW of seed activity in sPMCA, 2 μL different concentrations of TC-5RW were added to the 100 μL system. A 20 μL of each mixture was taken out and kept at –20 °C as a non-PMCA control. The remaining mixtures were subjected to sPMCA. Each cycle comprises a 20-s elapse time of sonication at amplitude 85 (250 W; Misonix S4000 sonicator) to sPMCA. Each cycle comprises a 20-s elapse time of sonication at amplitude 85 (250 W; Misonix S4000 sonicator) followed by an incubation period of 29 min 40 s at 37 °C to sPMCA. Each cycle comprises a 20-s elapse time of sonication at amplitude 85 (250 W; Misonix S4000 sonicator) while 263 K-infected hamster brain homogenate seeds or sCJDMM1- or sCJDMM2-infected human brain homogenate seeds were diluted at the ratios 1:100 (1 μL seed in 100 μL mix) as positive controls. To detect the inhibitory effect of TC-5RW of seed activity in sPMCA, 2 μL different concentration of TC-5RW was added to the 100 μL system. A 20 μL of each mixture was taken out and kept at –20 °C as a non-PMCA control. The remaining mixtures were subjected to sPMCA. Each cycle comprises a 20-s elapse time of sonication at amplitude 85 (250 W; Misonix S4000 sonicator) followed by an incubation period of 29 min 40 s at 37 °C and each round of sPMCA consisted of 80 cycles. For the sPMCA, 15-μL sample, each was aliquoted from the last cycle and placed into 65-μL fresh normal brain substrates for the next round of amplification.

Incubation of TC-5RW with Brain Homogenates

Ten percent (w/v) brain homogenates in lysis buffer from patients with different sCJD subtypes or 263 K-infected hamsters were incubated with TC-5RW at final concentrations ranging from 0–30 μg/mL for 37 °C, 400 rpm, or kept at –20 °C as designated hours. The samples were treated with PK at 100 μg/mL, 37 °C for an hour, followed by protease inhibition cocktail and boiled in the SDS sample buffer prior to Western blot analysis probing with the 3F4 antibody as shown below.

Two-Dimensional Western Blotting

Two-dimensional (2D) Western blotting of PrP was performed as previously described [14]. In brief, tissue homogenates were boiled in SDS sample buffer (3% SDS, 2 mM EDTA, 4% β-mercaptoethanol, 10% glycerol, 50 mM Tris, pH 6.8), followed by precipitation by 5 volumes of pre-chilled methanol at –20 °C for 2 h, then centrifugation at 14,000 rpm for 30 min at 4 °C. The pellets were resuspended in 50 μL reducing buffer (8 M urea, 2% CHAPS, 5 mM tributylphosphine, 20 mM Tris, pH 8.0) for 1 h at room temperature (RT), then added 5 μL iodoacetamide (200 mM) in dark at RT for more than 1 h. Five volumes of pre-chilled methanol were added and incubated at –20 °C for 2 h and centrifuged at 14,000 rpm for 30 min at 4 °C. The pellets were resuspended in 200 μL of rehydration buffer (7 M urea, 2 M thiourea, 1% DTT, 1% CHAPS, 1% Triton X-100, 1% ampholyte pH 3–10, trace of amount bromophenol blue) and centrifuged at 5000 rpm for 5 min at RT.

The samples were loaded onto the immobilized pH gradient strips for rehydration at RT for more than 12 h with gentle shaking. The first-dimensional isoelectric focusing was performed on the rehydrated gel strips for 7 h using a focusing tray. For the second dimension SDS-PAGE, the focused gel strips were equilibrated for 15 min each in equilibration buffer A (6 M urea, 2% SDS, 20% glycerol, 130 mM dithiothreitol, 0.375 M Tris–HCl, pH 8.8) and equilibration buffer B (6 M urea, 2% SDS, 20% glycerol, 135 mM iodoacetamide, 0.375 M Tris–HCl, pH 8.8), respectively. The equilibrated strips were loaded onto 15% Bio-Rad Criterion gels at 150 V for 90 min. The rest steps were the same as described below.

Western Blotting

To detect the PK-resistant PrP (PrPres), the samples were incubated with PK at 100 μg/mL at 37 °C for an hour, shaking at 450 rpm, followed by addition of protease inhibitor mixture cocktail (Roche), and boiling at SDS sample buffer for 10 min in order to terminate the PK reaction, while samples without PK treatment were added to the sample buffer directly to detect untreated PrP. Samples were loaded onto 15% Tris–HCl Criterion pre-cast gels (Bio-Rad) for SDS-PAGE. After SDS-PAGE, the proteins on the gels were transferred to Immobilon-P polyvinylidene difluoride (PVDF, Millipore) for 100 min at 0.35 A. After blocking in TBS-Tween-20 buffer at RT for an hour, the membranes were incubated at RT with anti-PrP antibody 3F4 at 1:40,000 dilution overnight. The membranes were washed with washing buffer (1× TBS, 0.1% Tween-20) for 5 min for 4 times, then incubated with horseradish peroxidase-conjugated sheep anti-mouse IgG at 1:3000 dilution at RT for 1 h, followed by washing 5 min for 4 times. The protein bands were visualized on Kodak film by ECL Plus following the product instruction.

Statistical Analysis

To quantify the protein level, Western blots were scanned with an Epson Expression 1680 scanner (Epson America, Inc, Los Alamitos, CA). Protein intensity on the Western blots was quantified by densitometric analysis with less exposed films to avoid protein signal saturation and subtracting the background of films using UN-SCAN-IT gel Analysis Software (Silk Scientific, Inc., Orem, UT). The statistical differences in intensity of PrP detected by Western blotting or ThT fluorescence of PrP aggregates among different groups were statistically analyzed.
using Student’s t-test or one-way ANOVA to obtain \( p \) values. All tests adopted a two-sided type I error level of 0.05.

**Results**

**TC-5RW-Treated Mice Have Much Longer Survival Time as well as Less PrP\( \text{Sc} \) Deposition and Spongiform Degeneration Than Vehicle-Treated Mice**

Cellulose ethers including TC-5RW are able to extend the survival time of prion-infected rodents [8, 10]. To determine whether a potential therapeutic effect could be reflected in the prion-seeding activity of skin tissues of infected animals treated with the compound, we intracerebrally inoculated hemizygous Tg7 mice with the 263 K prions. On the same day as inoculation, infected Tg mice were injected intraperitoneally with a single dose of TC-5RW at 50 mg (\( n = 8 \)) or with saline vehicle (\( n = 5 \)). The survival days post-inoculation of the 263 K-infected Tg mice expressing hamster PrP were significantly longer in the drug-treated group than the vehicle-treated mice when a single intraperitoneal injection was administered on the same day of intracerebral infection (170 (mean) ± 38 (SD) vs 72 ± 8, days post-inoculation, \( p < 0.0005 \)) (Fig. 1A). As previously reported by Doh-ura and co-workers, the compounds used in various combinations of timings and routes all exhibited a protective role in the infected animals [8]. To provide the proof-of-evidence, we selected one of the combinations for the compound administration in our current study. Our result indicated that TC-5RW effectively slowed the progression of the disease.

To determine how TC-5RW treatment affected PrP deposition and neuropathological changes in the brain of infected animals, we compared the PrP\( \text{Sc} \) deposition and spongiform degeneration in the brain of animals treated with TC-5RW or saline vehicle using PET blotting and H&E staining. Compared to vehicle-treated mice (Fig. 1B, right upper panels), the TC-5RW-treated mice exhibited substantially decreased PrP\( \text{Sc} \) staining in both the thalamus (TH) and the hippocampus (HP) brain regions (Fig. 1B, left upper panels). Remarkably, the spongiform degeneration was considerably decreased in the brain of TC-5RW-treated than vehicle-treated mice (Fig. 1B, lower panels). In sum, the TC-5RW treatment greatly prolonged the survival time and decreased PrP\( \text{Sc} \) deposition and neuronal lesions in the brain of prion-infected mice.

**Prion-Seeding Activity Is Undetectable in the Skin Tissues of 263 K-Infected Mice Treated with TC-5RW by RT-QuIC and sPMCA**

To determine whether the extended incubation periods associated with TC-5RW-treatment correlate with any changes in the levels of prion-seeding activity in the skin, next we performed highly sensitive RT-QuIC and sPMCA assays for detection of skin prion-seeding activity. The RT-QuIC result demonstrated that similar to the negative control (Neg CTL) all TC-5RW-treated mice (TC1-TC7) exhibited virtually no skin ThT reaction except for one (sample TC8) that showed a very weak ThT reaction after 55 h; in contrast, skin samples of all prion-infected control mice treated with vehicle (V1-V5) were found positive ThT reaction. Moreover, consistent with RT-QuIC assayed, 2–4 rounds of sPMCA detected no PrPres in the skin tissues of the TC-5RW-treated mice (TC1-TC8), but PrPres was detected in the skin from the vehicle-treated mice (V1-V5) (Fig. 2B–D). As controls, skin samples
of infected Tg mice amplified PrPsc while skin samples from non-infected (N1-N4), negative control (Neg), and samples without seeds (Bl) showed no PrPsc. Taken together, our RT-QuIC and sPMCA results indicate that TC-5RW treatment reduced the deposition and formation of PrPSc in the skin of infected Tg mice, reminiscent of its effect on brain PrPSc.

**TC-5RW Inhibits Skin Prion-Seeding Activity and PrPSc Amplification In Vitro**

Next, we determined whether the lack of detectable PrPSc-seeding activity in skin tissues of animals treated with TC-5RW is due to the inhibition of the PrPSc amplification by residual TC-5RW left in the skin. Based on the previous observation, approximately less than 0.5–1 mg of TC-5RW/gram tissue was expected to be left in the skin sample [8]. To test this possibility, we added different amounts of TC-5RW ranging from 0 to 50 μg/mL into the RT-QuIC in vitro assay of brain homogenates from 263 K-infected animals. Dose-dependent inhibitory effect of TC-5RW on ThT fluorescence intensity was observed (Fig. 3A).

We also examined the effect of TC-5RW on sPMCA of brain PrPSc in vitro. We added different amounts of TC-5RW in the sPMCA substrates, with 263 K-infected hamster brain homogenate as seeds, to verify the influence of TC-5RW on sPMCA of brain PrPSc. Compared to non-PMCA samples, amplification of PrPSc was only observed in the samples without TC-5RW but not in samples with different amounts of TC-5RW (Fig. 3B).

The same inhibitory effect of TC-5RW on prion-seeding activity was also detected by RT-QuIC assay in the skin samples. More than 50% ThT intensity of skin prion was inhibited in the presence of 2 μg/mL of TC-5RW while it was completely inhibited in the presence of 10 μg/mL or higher of TC-5RW (Fig. 3C). Moreover, the lag time of RT-QuIC was significantly increased compared to the sample without the compound (~38 vs ~8 h) (Fig. 3C).

**TC-5RW Treatment Does Not Affect 2D Profile of Brain PrP But Inhibits PrPSc Amplification by sPMCA In Vitro**

Two-dimensional (2D) gel electrophoresis coupled with Western blotting is a high-resolution technique that is able to reflect not only molecular weights but also charges of
proteins interested, molecular characteristics that can be affected by therapeutic compounds. To determine whether TC-5RW treatment changes molecular weight and charges of PrP in the brain of prion-infected mice, we compared the 2D gel profile of PrP molecules from mice administered with TC-5RW or saline vehicle. 2D gel electrophoresis and Western blotting showed no differences in 2D gel profiles between the two groups (Fig. 4A), suggesting that the compound affects no post-translational modification. Most of the diglycosylated PrP spots were located on the basic side with pI 6–10 and molecular weights at 33–35 kDa, while most of the mono-glycosylated PrP spots migrated in the acidic side pI 4–6.5 and molecular weights at 27–29 kDa (Fig. 4A).

Consistent with previous findings [8, 10], our RT-QuIC and sPMCA assays also revealed that TC-5RW inhibited seeding activity and amplification of PrPSc from both brain and skin tissues in vitro (Figs. 2 and 3). However, it is unknown whether the compound has any direct effect on PrPSc. To address this issue, we incubated brain homogenates of 263 K prion-infected hamster with different amounts of TC-5RW at 37 °C for 2 h. The levels of PrPres were determined by western blotting after PK treatment of hamster 263 K brain homogenates that were subjected to incubation with different amounts of TC-5RW. We observed that the incubation of brain homogenates with TC-5RW at as low as 4 μg/mL decreased the intensity of PrPres by approximately 80% when compared to untreated samples (Fig. 4B and 4C).

We also determined the effect of incubation time of TC-5RW with brain homogenates on the levels of PrPres. After incubation for 1 h, the levels of PrPres were decreased approximately 60% when compared to that at the time zero (Fig. 4D and 4E). In sum, incubation of TC-5RW with PrPSc can directly reduce the level of hamster PK-resistant PrPSc.

**TC-5RW Treatment Directly Decreases Human PK-Resistant PrPSc In Vitro**

To date, the inhibitory effect of CEs on PrPSc conversion has been observed in rodent and other animal prions, but no studies with human prions have been reported. Next, we determined whether TC-5RW has an inhibitory effect on human PrPSc. Different amounts of TC-5RW from 0–50 μg/mL were added into the sPMCA reaction in which PrPSc in brain homogenates from sCJDMM1 (MM1) or sCJDMM2 (MM2) were seeded in the normal brain homogenates of humanized Tg mice (Tg40h) expressing human wild-type PrPC with 129-MM polymorphism [22]. The PK-resistant PrPres was detected in the both sCJDMM1 and sCJDMM2 sPMCA products without TC-5RW. In contrast, no PrPres was detected in the sPMCA products of sCJDMM1 or sCJDMM2 in the presence of TC-5RW (Supplementary Fig. 1). Although PrPres was still detected in SCJDMM2 sPMCA product in the presence of 2 μg/mL of TC-5RW, its level was significantly decreased compared to that in the sample without TC-5RW.

To determine whether TC-5RW also has a direct effect on PK-resistant human PrPSc, the brain homogenates from sCJDMM1, sCJDMM2, sCJDVv2, sCJDvE200K, FFI, and fCJDv180I were incubated with different amounts of TC-5RW (0–30 μg/mL) at 37 °C for 2 h. The level of PK-resistant PrPSc was detected by Western blotting probed with the anti-PrP antibody 3F4 after PK treatment. Similar to hamster 263 K prion, in vitro TC-5RW
incubation significantly decreased the levels of PK-resistant PrPSc from various human prion diseases including most common subtypes of sCJD and fCJD at concentrations as low as 2 μg/mL, except for FFI that started to show a significant decrease at 6 μg/mL (Fig. 5). In addition, we also examined the effect of TC-5RW on human PrPres at −20 °C. Interestingly, after incubation of brain homogenates from sCJDVV2 with different amounts of TC-5RW from 0, 2, 4, 6, 8, 10, and 30 μg/mL, the levels of PrPres were also dramatically decreased (Supplementary Fig. 2).

TC-5RW Inhibits Seeding Activity of Prions from Various Human Prion Diseases In Vitro

We further investigated the effect of TC-5RW on the seeding activity of PrPSc from various human prion diseases including sCJDMM1, sCJDMM2, sCJDMMV2, sCJDVV2, fCJDf200K, FFI, and fCJDv180I by RT-QuIC assay (Fig. 6A through G). Although TC-5RW exhibited an inhibitory effect on prion-seeding activity in all human prion diseases, FFI and fCJDv180I had better inhibitory effects compared to various subtypes of sCJD and fCJDf200K in terms of the lag times (Supplementary Table 1) (Fig. 6H) and maximal intensity of ThT fluorescence at the endpoint of reaction (Supplementary Table 2) (Fig. 6I). Taken together, as done with hamster 263 K-prion, TC-5RW is also able to inhibit prion-seeding activity in various sporadic and genetic CJDs in vitro.

TC-5RW Inhibits Seeding Activity of Prions from CWD Deer In Vitro

Consistent with the previous study reported by Hannaoui et al. [10], we also found that TC-5RW was able to inhibit the seeding activity of PrPSc from CWD deer in the RT-QuIC assay. The compound significantly prolonged the lag time of ThT reaction upon an increase in the concentrations of TC-5RW (Supplementary Fig. 3). The ThT fluorescence intensity was significantly decreased at 30 μg/mL while no ThT reaction was detected at 50 μg/mL of TC-5RW (Supplementary Fig. 3).
**Discussion**

In addition to confirming the therapeutic effect of TC-5RW, a CE compound, on 263 K prion-infected animals, our current study made several important new findings. First, seeding activity and amplification of skin PrP<sub>Sc</sub> were significantly inhibited in 263 K-infected animals treated with TC-5RW, reflecting the reduced levels of PrP<sub>Sc</sub> in the brain after TC-5RW treatment. This may indicate prion seeding in the skin as a potential biomarker for monitoring the therapeutic efficacy of compounds. Second, TC-5RW exhibited an inhibitory effect on the seeding activity of PrP<sub>Sc</sub> from various human prion diseases including sporadic and genetic CJD as well as FFI, suggesting that it may have therapeutic potential for human prion diseases. We also confirmed its inhibitory effect on CWD prions. Finally, incubation of PrP<sub>Sc</sub> with TC-5RW directly decreased the level of PK-resistant PrP<sub>Sc</sub>, a function similar to detergents such as guanidine hydrochloride that may dissociate PrP<sub>Sc</sub> aggregates, suggesting that it may be used for decontamination of prions.

There are no cures for the fatal transmissible prion diseases including CJD in humans. The lack of an operational assay to assess the therapeutic efficacy in clinical trials of prion diseases limits screening effective compounds for the treatment. The pathogenesis and disease progression of prion disease are highly associated with the accumulation of PrP<sub>Sc</sub> in the brain. The current detection of PrP<sub>Sc</sub> mainly depends on examination of the brain tissues or maybe the cerebrospinal fluid (CSF) for prion-seeding activity by RT-QuIC assay. However, due to the high risks of complications by these highly invasive procedures, it may not be practical to use brain biopsy or lumbar puncture for routine follow-up in clinical trials. Remarkably, our recent study indicated that PrP<sub>Sc</sub> can be detected in the skin tissues of CJD patients [3] and could be a biomarker for early preclinical diagnosis of prion disease [5]. Our present study indicated that
Seeding activity and amplification capability of skin PrP<sub>Sc</sub> were undetectable when the Tg7 mice were given therapeutic compound TC-5RW and showed prolonged lifespan compared to vehicle-treated mice. This finding provided a proof-of-concept evidence that skin prion-seeding activity may serve as a biomarker for monitoring therapeutic efficacy in clinical trials of prion diseases. Biomarkers have been believed as critical to the discovery and development of disease therapeutics. For instance, skin prion-seeding activity could provide an early indication of therapeutic target brain prion improvement, thereby adjusting clinical trial design and allowing successful therapeutic development. Moreover, skin prion-seeding activity may also allow evaluating therapeutic intervention on disease progression. A skin punch biopsy is a less invasive procedure than a spinal tap; it can be conducted for outpatients. Therefore, detection of prions in the skin would be a highly valuable biomarker for evaluation of therapeutic efficacy in clinical trials, in addition to the diagnosis of prion diseases. This can be tested in human prion-infected humanized mice in the future.

Cellulose ethers (CEs) have already widely been used as inactive ingredients in foods and pharmaceuticals. It has been observed that CEs do not modify prion protein expression but inhibit PrP<sup>Sc</sup> formation in vitro and in prion-infected cells [8, 10]. Importantly, they have pre- or post-infection prophylactic effects and post-symptomatic therapeutic effects in prion-infected rodents [8]. Our current study observed that the CE compound TC-5RW is able to not only inhibit the seeding activity of PrP<sup>Sc</sup> but also directly decrease PK-resistant PrP<sup>Sc</sup> in various human prion diseases including the most common form of sCJD (sCJDMM1) and genetic CJD. Therefore, it is most likely that CEs can be used for clinical trials of human prion diseases. Especially, it will be of high clinical value for asymptomatic PrP mutation carriers since CEs have been proved to have pre-infection prophylactic effects in animals in the previous study [8]. Interestingly, we observed that TC-5RW showed a better inhibitory effect for two genetic prion diseases compared to other sCJD subtypes. However, this finding has not been validated in humans yet. Therefore, it will be interesting to determine whether CEs have a prophylactic effect in asymptomatic carriers of PrP mutations that are associated with various familial prion diseases. It has been known that most of these asymptomatic PrP mutation carriers will inevitably develop familial prion diseases during aging. It is possible that the incapability of RT-QuIC to detect skin prion-seeding activity in TC-5RW-treated Tg mice may partially result from the inhibitive effect of TC-5RW on seeding activity of RT-QuIC assay in vitro. However, our RT-QuIC assay revealed that the skin prion-seeding activity of RT-QuIC could not be completely inhibited until 50 μg/mL (Fig. 3A).

The exact mechanisms underlying extending survival time of infected animals by CEs remain unclear. Indeed, the levels of PK-resistant PrP<sup>Sc</sup> have been found to decrease compared to the infected animals without CE treatment [10], consistent with our current finding with PET blotting of brain tissue sections from infected animals. Moreover, TC-5RW has been observed to inhibit the prion amplification capability of sPMCA and seeding activity of PrP<sup>Sc</sup> seeds through RT-QuIC in vitro by previous studies [8, 10] and our current study. In addition, the inhibitory effect of CEs on PrP<sup>Sc</sup> formation also was found in a cell-based model of prion disease [8, 11]. However, the CE concentration required for the inhibitory effect was believed to be dependent on the approach used [8]. For instance, the CE concentration of less than 10 μg/g tissue equivalent was needed for inhibition of hamster PrP<sup>Sc</sup> in vivo and in vitro while it required ~1 mg/mL in the cell model [8]. Indeed, the decreased levels of PK-resistant PrP<sup>Sc</sup> in the brain of CWD-infected Tg mice were proposed to result from the alteration in the PK resistance of PrP<sup>Sc</sup> in the CE-treated mice [10]. However, it cannot be ruled out that the decrease in the levels of PK-resistant PrP<sup>Sc</sup> in the brain of the CEs-treated mice could just result from the inhibitory effect of CEs on the conversion of PrP<sup>C</sup> into PrP<sup>Sc</sup> or PrP<sup>Sc</sup> formation in vivo. This is because that the levels of PK-resistant PrP<sup>Sc</sup> will be decreased if the PrP<sup>Sc</sup> formation is inhibited in the brain of Tg mice treated by CE compounds. Our new finding that TC-5RW is able to directly decrease the PK-resistant PrP<sup>Sc</sup> by direct incubation of brain homogenates with TC-5RW may represent another mechanism involved in its therapeutic effect. However, our study by in vitro directly incubating TC-5RW with brain homogenates from 263 K-infected hamsters, CWD prion-infected deer, and various human prions-infected humans provided direct evidence that TC-5RW indeed alters PK resistance of PrP<sup>Sc</sup> either at 37 °C or even at −20 °C. The decrease in the levels of PK-resistant PrP<sup>Sc</sup> by the direct incubation of RT-5RW with brain homogenates is reminiscent of a phenomenon that has been well demonstrated with guanidine hydrochloride [25–27]. It is possible that as
guanidine hydrochloride, TC-5RW is also able to dissociate PrP<sub>Sc</sub> aggregates or change the conformation of PrP<sub>Sc</sub>. It has been shown that CEs induced the conformation transition of silk fibroin from random coil form to β-sheet structure [28]. In contrast, in the case of the effect of CEs on PrP<sub>Sc</sub> conformation, whether TC-5RW may induce conversion of β-sheet structure into α-helix structure remains to be determined.

Notably, the TC-5RW-treated mice with longer survival time had very milder cerebral lesions in the hippocampus and thalamus compared to the vehicle-treated mice. However, they were clinically in the terminal stage of the disease and died of prion disease ultimately. This apparent discrepancy may result from a possibility that TC-5RW may inhibit disease progression less effectively in the brainstem than in the cerebrum. This possibility will be clarified in the future. The other possibility is that TC-5RW may just reduce PK-resistant PrP<sub>Sc</sub> but not PK-sensitive PrP<sub>Sc</sub>, which may be echoed by the newly identified variably protease-sensitive prionopathy. The latter is characterized by the deposition in the brain of less PK-resistant PrP<sub>Sc</sub> but more PK-sensitive PrP<sub>Sc</sub> and exhibits a less severe brain damage and longer disease duration compared to sCJD [29–31].

**Abbreviations**
- PrP<sub>C</sub>: Cellular prion protein; PrP<sub>Sc</sub>: Scrapie isoform of prion protein; sCJD: Sporadic Creutzfeldt-Jakob disease; RT-QuIC: Real-time quaking-induced conversion; PMCA: Protein misfolding cyclic amplification; Tg: Transgenic; 2D: Two-dimensional electrophoresis

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s12035-021-02418-6.

**Acknowledgements** We thank all donors for brain tissues and the families affected by CJD as well as physicians for support. We also want to thank Dr. Zerui Wang for technical help at the early stage of this study and the National Prion Disease Pathology Surveillance Center, Case Western Reserve University, for providing the brain tissues from sCJD patients and normal controls.

**Author Contributions** W.Q.Z. conceived the study. M.D., K.D., L.C., and W.Q.Z. designed the study. M.D., K.T., H.W.L., W.Z., J.Y., A.O., A.F., M.V.C., M.M. K.D., L.C., and W.Q.Z. performed experiments and interpreted data analyses. M.V.C. and Q.K. provided brain tissues of humanized Tg40h mice. J.J.G. provided CWD brain tissues. M.D., K.D., L.C., and W.Q.Z. wrote the first version of the paper. All authors critically reviewed, revised, and approved the final version of the manuscript.

**Funding** This research was funded in part by CJD Foundation and ALZ/ARUK/MIFF/Weston to W.Q.Z, the National Institutes of Health R01NS109532 to W.Q.Z and Q.K, the National Natural Science Foundation of China (NNSFC) (No. 81671186) to L.C., and in part by the Japan Society for the Promotion of Science to K.T. (19K22479) and K.D. (19H03570), and the Japan Agency for Medical Research and Development to K.D. (16ek0109012h0003).

**Data Availability** All materials used in this study will be made available subject to a material transfer agreement.

**Declarations**

The use of autopsy human brain tissues was authorized by the Institutional Review Board of University Hospital Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio. The consents were received for each case through the National Prion Disease Pathology Surveillance Center (NPDPSC), Case Western Reserve University, Cleveland, Ohio, for research on retained tissues after written informed consents given by the patients during life or their next of kin after death. Postmortem examinations, if permission was available, were carried out in NPDPSC. All information was analyzed anonymously.

**Consent for Publication** The manuscript does not contain any individual person’s data in any form.

**Competing Interests** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Das AS, Zou WQ (2016) Prions: beyond a single protein. Clin Microbiol Rev 29(3):633–658. https://doi.org/10.1128/CMR.00046-15
2. Prusiner SB (1998) Prions. Proc Natl Acad Sci USA 95(23):13363–13383. https://doi.org/10.1073/pnas.95.23.13363
3. Orru CD, Yuan J, Appleby BS, Li B, Li Y, Winner D, Wang Z, Zhan YA et al (2017) Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease. Sci Transl Med. 9(417). https://doi.org/10.1126/scitranslmed.aam7785
4. Mammana A, Biaiardi S, Rossi M, Franceschini A, Donadio V, Capelleri S, Caughey B, Parchi P (2020) Detection of prions in skin punch biopsies of Creutzfeldt-Jakob disease patients. Ann Clin Transl Neurol 7(4):559–564. https://doi.org/10.1002/acn3.51000
5. Wang Z, Manca M, Foutz A, Camacho MV, Raymond GJ, Race B, Orru CD, Yuan J et al (2019) Early preclinical detection of prions in the skin of prion-infected animals. Nat Commun 10(1):247. https://doi.org/10.1038/s41467-018-08130-9
6. Arca HC, Mosquera-Giraldo LI, Bi V, Xu D, Taylor LS, Edgar KJ (2018) Pharmaceutical applications of cellulose ethers and cellulose ether esters. Biomacromol 19(7):2351–2376. https://doi.org/10.1021/acs.biomac.8b00517
7. Alshehri SM, Aldalbahi A, Al-Hajji AB, Chaudhary AA, Panhuis ML, Alhokbany N, Ahamad T et al (2018) Development of carbomethylcellulose-based hydrogel and nanosilver composite as antimicrobial agents for UTI pathogens. Carbohydr Polym 138:229–236. https://doi.org/10.1016/j.carbpol.2015.11.004
8. Teruya K, Oguma A, Nishizawa K, Kawata M, Sakasegawa Y, Kamitakahara H, Doh-Ura K (2016) A single subcutaneous injection of cellulose ethers administered long before infection conferred...
sustained protection against prion diseases in rodents. PLoS Pathog 12(12):e1006045. https://doi.org/10.1371/journal.ppat.1006045

9. Abdulrahman BA, Tahir W, Doh-Ura K, Gilch S, Schatzl HM (2019) Combining autophagy stimulators and cellulose ethers for therapy against prion disease. Prion 13(1):185–196. https://doi.org/10.1080/19336896.2019.1670928

10. Hannauoi S, Arihni MI, Chang SC, Yu J, Gopakalirishnan P, Doh-Ura K, Schatzl HM, Gilch S (2020) Cellulose ether treatment in vivo generates chronic wasting disease prions with reduced protease resistance and delayed disease progression. J Neurochem 152(6):727–740. https://doi.org/10.1111/jnc.14877

11. Nishizawa K, Teruya K, Oguma A, Sakasegawa Y, Schatzl H, Gilch S, Doh-Ura K (2019) Preparation and characterization of cellulose ether liposomes for the inhibition of prion formation in prion-infected cells. J Pharm Sci 108(8):2814–2820. https://doi.org/10.1016/j.xphs.2019.03.025

12. Kascakaj RJ, Rubenstein R, Merz PA, Tonna-DeMasi M, Fersko R, Carp RI, Wissniewski HM, Diringer H (1987) Mouse polyclonal antibody to scrapie-associated fibril proteins. J Virol 61(12):3688–3693. https://doi.org/10.1128/JVI.61.12.3688-3693.1987

13. Zou WQ, Langeveld J, Xiao X, Chen S, McGeer PL, Yuan J, Payne MC, Kang HE et al (2010) PRP conformational transitions alter species preference of a PrP-specific antibody. J Biol Chem 285(18):13874–13884. https://doi.org/10.1074/jbc.M109.088831

14. Yuan J, Xiao X, McGechan J, Dong Z, Cali I, Fujisoka H, Kong Q, Kneale G et al (2006) Insoluble aggregates and protease-resistant conformers of prion protein in uninfected human brains. J Biol Chem 281(46):34848–34858. https://doi.org/10.1074/jbc.M602238200

15. Race RE, Priola SA, Bessen RA, Ernst D, Dockter J, Rall GF, Mucke L, Chesbro B et al (1995) Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron 15(5):1183–1191. https://doi.org/10.1016/0896-6273(95)00105-1

16. Bueler H, Fischer M, Lang Y, Bluthmann H, Lipp HP, DeArmond SJ, Prusiner SB, Aguet M et al (1992) Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356(6370):577–582. https://doi.org/10.1038/356577a0

17. Kawasaki Y, Kawagoe K, Chen CJ, Teruya K, Sakasegawa Y, Doh-Ura K (2007) Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals challenged with scrapie. J Virol 81(23):12889–12898. https://doi.org/10.1128/JVI.01563-07

18. Kimura T, Nishizawa K, Oguma A, Nishimura Y, Sakasegawa Y, Teruya K, Nishijima I, Doh-ura K (2015) Secretin receptor involvement in prion-infected cells and animals. FEBS Lett 589(15):2011–2018. https://doi.org/10.1016/j.febslet.2015.05.039

19. Mammadova N, Cassmann E, Greenlee JJ (2020) Successful transmission of the chronic wasting disease (CWD) agent to white-tailed deer by intravenous blood transfusion. Res Vet Sci 133:304–306. https://doi.org/10.1016/j.rvsc.2020.10.009

20. Hamir AN, Richt JA, Miller JM, Kunkle RA, Hall SM, Nicholson EM, O’Rourke KE, Greenlee JJ et al (2008) Experimental transmission of chronic wasting disease (CWD) of elk (Cervus elaphus nelsoni), white-tailed deer (Odocoileus virginianus), and mule deer (Odocoileus hemionus hemionus) to white-tailed deer by intracerebral route. Vet Pathol 45(3):297–306. https://doi.org/10.1354/vp.45-3-297

21. Moore SJ, Kunkle R, Greenlee MH, Nicholson E, Richt J, Hamir A, Waters WR, Greenlee J (2016) Horizontal transmission of chronic wasting disease in reindeer. Emerg Infect Dis 22(12):2142–2145. https://doi.org/10.3201/eid2212.160635

22. Kong Q, Zheng M, Casalone C, Qing L, Huang S, Chakraborty B, Wang P, Chen F et al (2008) Evaluation of the human transmission risk of an atypical bovine spongiform encephalopathy prion strain. J Virol 82(7):3697–3701. https://doi.org/10.1128/JVI.02561-07

23. Castillo J, Saa P, Hetz C, Soto C (2005) In vitro generation of infectious scrapie prions. Cell 121(2):195–206. https://doi.org/10.1016/j.cell.2005.02.011

24. Yuan J, Zhan YA, Abskharon R, Xiao X, Martinez MC, Zhou X, Kneale G, Mukol J et al (2013) Recombinant human prion protein inhibits prion propagation in vitro. Sci Rep 3:2911. https://doi.org/10.1038/srep02911

25. Choi YP, Peden AH, Groner A, Ironside JW, Head MW (2010) Distinct stability states of disease-associated human prion protein identified by conformation-dependent immunoassays. J Virol 84(22):12030–12038. https://doi.org/10.1128/JVI.01057-10

26. Peretz D, Scott MR, Groth D, Williamson RA, Burton DR, Cohen FE, Prusiner SB (2001) Strain-specific relative conformational stability of the scrapie prion protein. Protein Sci 10(4):854–863. https://doi.org/10.1101/jgs.39201

27. Zou WQ, Zheng J, Gray DM, Gambetti P, Chen SG (2004) Antibody to DNA detects scrapie but not normal prion protein. Proc Natl Acad Sci USA 101(5):1380–1385. https://doi.org/10.1073/pnas.0307825100

28. Shetty GR, Rao BL, Asha S, Wang Y, Sangappa Y (2015) Preparation and characterization of silk fibroin/hydroxypropyl methyl cellulose (HPMC) blend films. Fibers and Polymers 16(8):1734–1741

29. Gambetti P, Dong Z, Yuan J, Xiao X, Zheng M, Alshekhlee A, Castellani R, Cohen M et al (2008) A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol 63(6):697–708. https://doi.org/10.1002/ana.21420

30. Zou WQ, Puoti G, Xiao X, Yuan J, Qing L, Cali I, Shimoji M, Langeveld J et al (2010) Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol 68(2):162–172. https://doi.org/10.1002/ana.22094

31. Head MW, Yull HM, Ritchie DL, Langeveld JP, Fletcher NA, Knight RS, Ironside JW (2013) Variably pro tease-sensitive prionopathy in the UK: a retrospective review 1991–2008. Brain 136(Pt4):1102–1115. https://doi.org/10.1093/brain/aws366

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.